WEBULL
WebtradeDownload

What Bristol Myers Squibb Stock’s Strong Buy Upgrade Means For Shareholders

Simply Wall St · 1d ago
  • In recent weeks, Bristol-Myers Squibb reported two-year Phase 3 POETYK PsA-2 data for Sotyktu in psoriatic arthritis, expanded access to ZENBEXUS through a restricted REMS network, and affirmed a quarterly dividend of US$0.63 per share payable in November 2026.
  • These updates highlight Bristol-Myers Squibb’s mix of late-stage immunology progress, controlled specialty distribution in oncology, and continued cash returns through ongoing dividend payments.
  • We will explore how Bristol-Myers Squibb’s raised earnings estimates and Zacks Rank upgrade interact with this broader investment narrative.
Spot opportunities that echo Bristol-Myers Squibb’s mix of late-stage pipelines and income potential by scanning our hand picked 30 high quality undervalued stocks.

Bristol-Myers Squibb Investment Narrative Recap

To own Bristol-Myers Squibb, you need to be comfortable with a mature pharma group that is working to offset looming patent expiries by turning late stage programs like Sotyktu into durable franchises. The short term hinge is clear. Management needs continued clinical and commercial traction from newer products as revenue and earnings are forecast to decline over the next three years.

The biggest operational risk sits in that gap between expiring blockbusters and replacement therapies. Recent Sotyktu PsA-2 data help the story but do not remove concentration risk in oncology and cardiovascular. The latest dividend affirmation underlines a commitment to cash returns, although higher debt and one off charges keep balance sheet quality in focus.

The two year POETYK PsA-2 update for Sotyktu looks like the most relevant recent announcement. Bristol-Myers Squibb is trying to turn this TYK2 inhibitor into a multi indication pillar alongside psoriasis, so durable efficacy and a consistent safety profile through Week 104 matter for physician confidence and payer discussions.

For catalysts, investors are watching how quickly Sotyktu use in psoriatic arthritis scales against entrenched biologics and oral options. Strong responses across ACR20/50/70 and minimal disease activity give the drug clinical footing, but execution still depends on label breadth, formulary access and whether these results help offset pressure from patent cliffs in the wider portfolio.

Bristol-Myers Squibb's current analyst narrative points to revenues of US$40.0b and earnings of US$8.3b by 2029, based on a forecast yearly revenue decline of 6.6% and an earnings decrease of US$1.0b from US$9.3b today.

Uncover why Bristol-Myers Squibb's fair value indicates an 8% potential upside to its current price, a discount that could narrow faster than expected.

NYSE:BMY 1-Year Stock Price Chart
NYSE:BMY 1-Year Stock Price Chart

Exploring Other Perspectives

You see the patent cliff as the main hazard for Bristol-Myers Squibb. The most pessimistic analysts push that even further. Before this Sotyktu and ZENBEXUS news, they were penciling in revenue of about US$36.8b and earnings of US$4.7b by 2029, which is a sharply harsher story than the consensus. These new data and distribution moves could shift both narratives. It can be useful to weigh several viewpoints before deciding how much risk you are comfortable with.

Explore 3 other Bristol-Myers Squibb fair value estimates, including one that suggests it could be worth just $66.21.

Decide For Yourself

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking For More Investment Ideas Beyond Bristol-Myers Squibb?

If the Bristol-Myers Squibb story has you thinking about how to balance pipelines, cash flow and dividends in your own portfolio, it can help to scan a wider set of candidates using a focused stock screener.

  • For income seekers who still want resilience on the balance sheet, start with a 8 dividend fortresses that screens for payout strength alongside financial durability.
  • If capital preservation sits higher on your priority list, tighten your risk profile by reviewing 30 resilient stocks with low risk scores that score well on stability and downside protection.
  • When you want quality but are wary of overpaying, broaden your watchlist with a 16 high quality undiscovered gems that filters for robust fundamentals at less crowded valuations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.